Washington, D.C. – March 27, 2019 – A proposed rule issued by the U.S. Food and Drug Administration (FDA) today would modernize mammography quality standards and address breast density reporting to patients and their health care providers.
ACS CAN is concerned about a recent administration announcement affirming a district court decision to overturn the health care law.
Washington, D.C. – The U.S.
Washington, D.C. – The White House has announced its intention to appoint Dr. Ned Sharpless, current director of the National Cancer Institute (NCI), as acting commissioner of the Food and Drug Administration (FDA). Dr.
The administration released its FY20 budget today including a $4.7 billion cut for medical research at the National Institutes of Health (NIH) including a nearly $900 million cut for the National Cancer Institute (NCI).
Washington, D.C. – March 6, 2019 – Bipartisan legislation introduced today in the U.S. Senate and House of Representatives would ensure that surprise out-of-pocket expenses are not a barrier to lifesaving colorectal cancer screenings for seniors on Medicare.
WASHINGTON, D.C. – In a major victory for the nation’s health and the fight against tobacco, a federal court on Tuesday ordered the U.S. Food and Drug Administration (FDA) to issue a final rule mandating graphic health warnings on cigarette packs and advertising by March 15, 2020.
Washington, D.C. – Following is a statement from Lisa Lacasse, president of the American Cancer Society Cancer Action Network (ACS CAN), responding to reports that Food and Drug Administration (FDA) Commissioner Scott Gottlieb is resigning:
Today the American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Department of Health and Human Services (HHS) on the Notice of Benefit and Payment Parameters, which would set the rules for health care plans in 2020.
A research team led by the Fred Hutchinson Cancer Research Center have determined the most significant barriers to clinical trial participation. The study published in Journal of the National Cancer Institute (JNCI) upends the notion that patient factors are the driving forces behind why most clinical trials don’t meet their enrollment targets.